Not Yet RecruitingNot Applicable

Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery

80 participantsStarted 2024-05-01

Plain-language summary

The study objective is to compare standard CABG to a hybrid revascularization strategy (RA-MIDCAB + PCI) in patients who have multi-vessel CAD and an indication for surgery, but who have a slightly higher risk of post-operative complications.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Multi-vessel CAD with an indication for revascularization,
✓. Presence of at least 1 risk factor for increased risk of post-operative death or major complication,
✓. Coronary artery anatomy appropriate for a robotically-assisted MIDCAB or regular CABG, vessels other than the left anterior descending with lesions amenable to either CABG or PCI.

Exclusion criteria

✕. Significant left main coronary artery disease,
✕. Ejection fraction \< 30%,
✕. Patients with GFR \< 30,
✕. Patients unable to take dual anti-platelet agents due to high bleeding risk,
✕. Patients requiring emergent surgery, including patients with hemodynamic instability,
✕. Patients with anatomy not suitable for a robotically-assisted approach (by CT chest).

What they're measuring

Post-operative Length of Stay

Timeframe: From end of surgery (Skin time) to hospital discharge time, assessed up to 30 days

Trial details

NCT IDNCT06378775

SponsorCardiology Research UBC

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-05-01

View on ClinicalTrials.gov More Coronary Artery Disease trials